Want to see PRE full AI Analyst Report?
Top Page
Prenetics Group
(NASDAQ:PRE)
Select Model
Select Model
Rating:59Neutral
Price Target:
$21.00
▲(12.06% Upside)
Action:Reiterated
Date:08/24/26
The score is held back primarily by weak financial performance (persistent losses and multi-year cash burn), partially offset by a strong earnings-call outlook with raised guidance, improving unit economics, and secured financing support. Technicals are moderately constructive with price above key moving averages, while valuation remains difficult to justify on current earnings due to a negative P/E and no dividend support.
Positive Factors
Accelerating Revenue Growth
Rapid revenue expansion and higher full-year guidance indicate strong adoption of IM8 and improving commercial scale. Initiated 2027 guidance above $400M also supports a durable multi-year growth outlook if execution continues.
Negative Factors
Persistent Losses and Cash Burn
Prenetics remains materially loss-making despite stronger revenue and margins. Continued operating cash burn can constrain reinvestment and financial flexibility, making sustainable profitability a key execution requirement over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Rapid revenue expansion and higher full-year guidance indicate strong adoption of IM8 and improving commercial scale. Initiated 2027 guidance above $400M also supports a durable multi-year growth outlook if execution continues.
Read all positive factors
Prenetics Group (PRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$346.30M
Dividend YieldN/A
Average Volume (3M)216.11K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue Growth182.05%
EPS Growth-5.43%
CountryUS
Employees98
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-4.16
Shares Outstanding15,562,491
10 Day Avg. Volume398,992
30 Day Avg. Volume216,110
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.27
Price to Sales (P/S)2.40
P/FCF Ratio-10.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$37.00Price Target Upside97.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$222.53M
Prenetics Group Business Overview & Revenue Model
Company Description
Prenetics Group Limited (Nasdaq: PRE) is a healthcare and life sciences company focused on diagnostics and genomic testing. The company provides products and services in areas such as genetic testing, disease screening, and related laboratory diag...
How the Company Makes Money
Prenetics makes money primarily by selling diagnostic and genetic testing products and services. Revenue is generated when (a) consumers purchase testing kits or services directly (e.g., at-home or consumer-initiated testing where available), and ...
Prenetics Group Earnings Call Summary
Earnings Call Date:Aug 18, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call presented a strong growth story with multiple concrete operational and commercial milestones: record revenues, dramatic customer growth, improving unit economics, raised guidance, a $1B financing commitment, and ongoing clinical trials that enhance credibility. The primary negatives are high near-term marketing-driven losses, dependence on financing to fund customer acquisition, and the relative youth of cohorts and trials (outcomes pending). On balance, the material upward momentum, improving metrics (CAC, margins, contribution profit), and secured funding outweigh the current losses and risks.Positive Updates
Record Revenue and Rapid Growth
Q2 total revenue $46.5M (up 29% sequential, ~3.9x YoY). IM8 revenue $45M (up 33% sequential). July was the strongest month: ~$21M revenue (CEO cited $20.9M), annualized run-rate ~ $251M.
Negative Updates
High Marketing Spend Driving Losses
Acquisition marketing expense was $36.2M in Q2 (≈78% of sales). Adjusted EBITDA for Q2 was negative ~$19M and first-half adjusted EBITDA loss was ~$24.6M; company expects H2 adjusted EBITDA loss of -$8M to -$12M (improvement expected but still negative).
Read all updates
Q2-2026 Updates
Positive
Negative
Record Revenue and Rapid Growth
Q2 total revenue $46.5M (up 29% sequential, ~3.9x YoY). IM8 revenue $45M (up 33% sequential). July was the strongest month: ~$21M revenue (CEO cited $20.9M), annualized run-rate ~ $251M.
Read all positive updates
Company Guidance
Management raised full‑year 2026 revenue guidance to $220–230M (IM8 $215–222M) and initiated 2027 guidance of $400M+, while guiding Q3 IM8 revenue of $61.5–62.5M (Prenetics $63–64M) with an implied Q4 of ~$81.2M; Q2 revenue was $46.5M (IM8 $45M), +29% sequential and 3.9x year‑over‑year, with 65% gross margin and ~46% contribution margin. The company added ~118k new customers in Q2 (July cohort ~47k), reached ~140k active subscribers, and hit a July monthly revenue near $21M (monthly run‑rate ≈ $251M after July); CAC improved to ~$239 in July (vs ~$301 in Q2, ~$305 in Q1) and each $1 of acquisition spend has returned ~$1.52 of gross profit to date. General Catalyst committed $1B (funding ~70% of acquisition spend), July showed adjusted free‑cash‑flow positivity, the balance sheet held ~$109M of cash/current financial assets, and management expects H2 adjusted EBITDA loss to narrow to roughly negative $8M–$12M (vs H1 ≈ negative $24.6M).Prenetics Group Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 142.56M | 92.39M | 30.62M | 21.74M | 13.16M | 12.53M |
| Gross Profit | 89.25M | 48.79M | 15.40M | 8.83M | 3.62M | 3.60M |
| EBITDA | -62.52M | -32.19M | -51.57M | -47.90M | -218.04M | -209.16M |
| Net Income | -67.61M | -37.71M | -46.30M | -62.72M | -190.45M | -174.01M |
Balance Sheet | ||||||
| Total Assets | 153.66M | 203.52M | 213.57M | 254.17M | 312.13M | 148.51M |
| Cash, Cash Equivalents and Short-Term Investments | 109.39M | 61.49M | 62.81M | 72.74M | 184.12M | 45.19M |
| Total Debt | 682.00K | 2.20M | 5.77M | 2.37M | 6.65M | 491.67M |
| Total Liabilities | 60.73M | 29.01M | 42.23M | 44.01M | 68.67M | 549.40M |
| Stockholders Equity | 93.01M | 174.60M | 170.39M | 206.36M | 237.06M | -400.81M |
Cash Flow | ||||||
| Free Cash Flow | -34.14M | -22.02M | -29.94M | -14.68M | 8.17M | 2.00M |
| Operating Cash Flow | -49.39M | -21.81M | -28.87M | -13.76M | 14.51M | 13.42M |
| Investing Cash Flow | 54.97M | -35.79M | 38.54M | -82.95M | -46.14M | -22.02M |
| Financing Cash Flow | 1.42M | 37.54M | -3.34M | -4.70M | 143.32M | 29.32M |
Prenetics Group Technical Analysis
Positive
18.74
Price Trends
19.14
Positive
18.63
Positive
17.78
Positive
Market Momentum
0.06
Negative
56.53
Neutral
42.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRE, the sentiment is Positive. The current price of 18.74 is below the 20-day moving average (MA) of 18.82, below the 50-day MA of 19.14, and above the 200-day MA of 17.78, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 56.53 is Neutral, neither overbought nor oversold. The STOCH value of 42.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRE.
Prenetics Group Risk Analysis
Prenetics Group disclosed 58 risk factors in its most recent earnings report. Prenetics Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our securities may be delisted from NASDAQ as a result of our failure of meeting the NASDAQ continued listing requirements. Q4, 2023
2.
Our securities may be prohibited from being traded in the United States under the Holding Foreign Companies Accountable Act in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The Holding Foreign Companies Accountable Act, as amended by the Consolidated Appropriations Act, 2023, decreased the number of "non-inspection years" from three years to two years, and thus, reduced the time before our securities may be prohibited from trading or delisted. The delisting of our securities, or the threat of them being delisted, may materially and adversely affect the value of your investment. Q4, 2023
3.
You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under the laws of the Cayman Islands, we conduct substantially all of our operations, and a majority of our directors and executive officers reside, outside of the United States. Q4, 2023
Prenetics Group Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | $346.30M | -4.86 | -46.74% | ― | 182.05% | -5.43% | |
54 Neutral | $943.54M | -11.05 | -61.65% | ― | -51.05% | 57.25% | |
51 Neutral | $191.86M | -9.66 | -121.62% | ― | 20.83% | 9.70% | |
50 Neutral | $228.59M | -6.98 | -150.56% | ― | 39.59% | 61.06% | |
50 Neutral | $102.87M | -1.17 | -10.96% | ― | -0.21% | 75.40% | |
45 Neutral | $38.17M | -1.11 | 402.97% | ― | 12.75% | 16.23% |
* Consumer Defensive Sector Average
PRE
Prenetics Group
20.20
12.87
175.58%
ACRS
Aclaris Therapeutics
6.41
4.61
256.11%
MDXH
MDxHealth
0.74
-2.80
-79.01%
STIM
Neuronetics
3.00
-0.20
-6.25%
XGN
Exagen
7.92
-1.93
-19.59%
BNR
Burning Rock Biotech
9.78
1.18
13.72%
Prenetics Group Corporate Events
Prenetics’ IM8 Brings Lily Collins On Board as Global Ambassador and Shareholder Amid Raised 2026–2027 Guidance
Aug 20, 2026
Prenetics Global Limited, the parent of premium health and longevity brand IM8, operates in the consumer health sector with a focus on science-backed daily nutrition systems. Co-founded with David Beckham, IM8’s flagship Daily Ultimate Essen...
Prenetics’ IM8 Drives 288% Q2 Revenue Surge and Turns Cash Flow Positive
Aug 18, 2026
On August 18, 2026, Prenetics reported unaudited second-quarter 2026 results showing total revenue of $46.5 million, up about 288% year-on-year and in line with guidance. IM8 accounted for $45.0 million, rising roughly 359% year-on-year and markin...
Prenetics Names Veteran Wall Street Analyst Caroline Levy to Board as Independent Director
Aug 17, 2026
On August 17, 2026, Prenetics Global Limited announced the appointment of veteran Wall Street consumer analyst Caroline Levy as an independent director to its Board. Levy, known for more than 30 years of equity research experience and leadership r...
Prenetics Secures $1 Billion General Catalyst Growth Financing for IM8 Business
Aug 7, 2026
On July 14, 2026, Prenetics Global Limited announced it had closed a $1 billion growth financing arrangement with General Catalyst’s Customer Value Fund to support the sales and marketing expansion of its IM8 business. The deal, documented i...
Prenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook Rises
Jul 14, 2026
On July 14, 2026, Prenetics announced that IM8 has closed a $1 billion growth financing arrangement with General Catalyst’s Customer Value Fund, a non-dilutive facility designed to finance up to 70% of IM8’s global marketing spend. The...
Prenetics Posts Record Q1 2026 as IM8 Surges and Guidance Raised
Jun 10, 2026
On June 10, 2026, Prenetics reported record first-quarter 2026 results, with revenue from continuing operations of $36.0 million and gross profit of $23.3 million, driven largely by IM8’s $33.8 million in revenue, up 23.1% quarter-on-quarter...
Prenetics Adds DTC Pioneer Hudson Leogrande to Board as IM8 Scales Social Commerce Push
Jun 4, 2026
On June 4, 2026, Prenetics Global Limited announced changes to its board, with director David Vanderveen resigning and Hudson Leogrande, founder and CEO of fast-growing DTC apparel brand Comfrt, joining as an independent director. With Leogrande&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.